New Leaf Venture Partners Trimmed Its Sage Therapeutics (SAGE) Stake as Share Price Rose; Hite Hedge Asset Management Stake in American Midstream Partners (AMID) Lifted as Valuation Declined

February 15, 2018 - By Marguerite Chambers

Hite Hedge Asset Management Llc increased its stake in American Midstream Partners (AMID) by 57.06% based on its latest 2017Q3 regulatory filing with the SEC. Hite Hedge Asset Management Llc bought 269,107 shares as the company’s stock declined 17.59% while stock markets rallied. The hedge fund held 740,756 shares of the public utilities company at the end of 2017Q3, valued at $10.11M, up from 471,649 at the end of the previous reported quarter. Hite Hedge Asset Management Llc who had been investing in American Midstream Partners for a number of months, seems to be bullish on the $678.72M market cap company. The stock decreased 0.78% or $0.1 during the last trading session, reaching $12.65. About 73,671 shares traded. American Midstream Partners, LP (NYSE:AMID) has risen 15.28% since February 15, 2017 and is uptrending. It has underperformed by 1.42% the S&P500.

Robert Boucai decreased its stake in Sage Therapeutics Inc (SAGE) by 33.89% based on its latest 2017Q3 regulatory filing with the SEC. New Leaf Venture Partners Llc sold 23,000 shares as the company’s stock rose 0.86% with the market. The hedge fund run by Robert Boucai held 44,872 shares of the health care company at the end of 2017Q3, valued at $2.80 million, down from 67,872 at the end of the previous reported quarter. New Leaf Venture Partners Llc who had been investing in Sage Therapeutics Inc for a number of months, seems to be less bullish one the $7.55B market cap company. The stock increased 1.08% or $1.77 during the last trading session, reaching $165.9. About 4,893 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since February 15, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

Hite Hedge Asset Management Llc, which manages about $778.61 million and $387.03 million US Long portfolio, decreased its stake in Alon Usa Partners Lp (NYSE:ALDW) by 250,194 shares to 138,681 shares, valued at $1.60 million in 2017Q3, according to the filing. It also reduced its holding in Usd Partners Lp by 141,924 shares in the quarter, leaving it with 70,788 shares, and cut its stake in Rice Energy Inc (NYSE:RICE).

Investors sentiment increased to 0.94 in 2017 Q3. Its up 0.42, from 0.52 in 2017Q2. It improved, as 4 investors sold AMID shares while 13 reduced holdings. 6 funds opened positions while 10 raised stakes. 29.93 million shares or 2.69% more from 29.15 million shares in 2017Q2 were reported. Glob X Management Com Limited Liability Corp owns 780 shares. Clearbridge Lc reported 388,888 shares. Price Michael F accumulated 685,499 shares. United Kingdom-based Barclays Public Limited has invested 0% in American Midstream Partners, LP (NYSE:AMID). Jpmorgan Chase And Company invested 0% in American Midstream Partners, LP (NYSE:AMID). Eagle Global Limited Company reported 10,000 shares or 0% of all its holdings. Hite Hedge Asset Mgmt Llc holds 740,756 shares. Peak6 Limited Partnership owns 12,461 shares. Guggenheim Lc has invested 0% in American Midstream Partners, LP (NYSE:AMID). 39,958 are owned by Royal Bancorp Of Canada. Regent Invest Management Ltd holds 11,756 shares or 0.05% of its portfolio. Raymond James Finance Svcs Advsr reported 28,367 shares stake. Rafferty Asset Management Limited Liability Co owns 0.06% invested in American Midstream Partners, LP (NYSE:AMID) for 200,636 shares. Advisory Rech has invested 0.29% in American Midstream Partners, LP (NYSE:AMID). Grp One Trading Lp has 9,224 shares.

Among 9 analysts covering American Midstream Partners LP (NYSE:AMID), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. American Midstream Partners LP had 23 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by Barclays Capital on Monday, November 16 with “Overweight”. The stock of American Midstream Partners, LP (NYSE:AMID) earned “Overweight” rating by Barclays Capital on Wednesday, August 12. The firm earned “Equal Weight” rating on Monday, January 11 by Barclays Capital. RBC Capital Markets initiated American Midstream Partners, LP (NYSE:AMID) on Friday, August 19 with “Outperform” rating. The company was downgraded on Tuesday, March 15 by Ladenburg Thalmann. On Sunday, July 23 the stock rating was maintained by RBC Capital Markets with “Buy”. RBC Capital Markets maintained it with “Hold” rating and $14.0 target in Sunday, November 5 report. The company was maintained on Tuesday, October 25 by RBC Capital Markets. The stock has “Neutral” rating by Citigroup on Thursday, November 19. As per Friday, December 2, the company rating was upgraded by Citigroup.

Since December 14, 2017, it had 0 insider buys, and 2 selling transactions for $17.36 million activity. Kanes Stephen also sold $7.80M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) shares.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on February, 22. They expect $-2.04 earnings per share, down 36.00% or $0.54 from last year’s $-1.5 per share. After $-1.97 actual earnings per share reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3.55% negative EPS growth.

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics had 52 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by Needham with “Buy” on Tuesday, September 12. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Cowen & Co on Tuesday, September 5. The stock has “Buy” rating by Needham on Tuesday, June 13. The rating was maintained by Bank of America on Thursday, November 16 with “Buy”. The firm earned “Buy” rating on Thursday, December 7 by Cowen & Co. The firm earned “Strong Buy” rating on Wednesday, December 14 by Raymond James. The firm has “Buy” rating given on Friday, August 4 by Canaccord Genuity. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Wednesday, January 31 by BMO Capital Markets. As per Thursday, December 7, the company rating was maintained by SunTrust. Cowen & Co maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Tuesday, September 12. Cowen & Co has “Buy” rating and $90.0 target.

New Leaf Venture Partners Llc, which manages about $872.85 million and $215.48M US Long portfolio, upped its stake in Irhythm Technologies Inc by 37,776 shares to 703,741 shares, valued at $36.51 million in 2017Q3, according to the filing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: